Bloemendaal, Noord-Holland, The Netherlands Biotech Turnaround Fund (BTF) appeared to be the VC, which was created in 2000. The leading representative office of defined VC is situated in the Bloemendaal. The company was established in Europe in The Netherlands.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Medical Device, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Genizon BioSciences, CymaBay Therapeutics.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Biotech Turnaround Fund (BTF), startups are often financed by MVI Finance, HBM Healthcare Investments AG, Carnegie Asset Management. The meaningful sponsors for the fund in investment in the same round are HBM Healthcare Investments AG, Investissement Desjardins, MVI Finance. In the next rounds fund is usually obtained by HBM Healthcare Investments AG, MVI Finance, BioFund Management.
Considering the real fund results, this VC is 6 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2003. The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Biotech Turnaround Fund (BTF) works on 15 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2014.
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
CymaBay Therapeutics | $27M | 29 Aug 2003 | Hayward, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
CymaBay Therapeutics | $27M | 29 Aug 2003 | Hayward, California, United States |
